Schrödinger CEO Ramy Farid rethinks role of AI in drug discovery

In a recent STAT AI Prognosis newsletter, Schrödinger chief executive Ramy Farid discussed how his perspective on artificial intelligence is evolving. He reflected on recent conversations about AI in health and medicine and shared his thoughts on the technology’s future impact.

Farid predicts that within five years the industry will have a clearer sense of what AI can realistically achieve. He expects hype to subside and for tools that do not deliver value to be abandoned.

He also suggested that companies will stop forcing employees to use AI systems that are not effective, which should reduce uncertainty in the job market and improve overall confidence in AI applications.

The commentary underscores a broader shift toward more pragmatic adoption of AI in pharmaceutical research and development.